{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-013838","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2022-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.156063+00:00","generated_at":"2026-06-23T22:12:25.963987+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fennec closes $5M initial tranche of $45M senior secured note; $20M on FDA approval of PEDMARK","bullets":["First closing $5M senior secured note; $20M upon FDA approval of PEDMARK; up to $20M additional.","Notes convertible at $8.11/share (20% premium to VWAP); interest greater of Prime or 3.5% + 4.5% margin, 24 months PIK.","Matures Aug 1, 2027; company redemption at 110% before Aug 2026, 107.5% thereafter; change-of-control put.","Repaid all Bridge Bank secured debt with first closing proceeds.","Commitment fee 2% – half in warrants for 55,498 shares at $8.11, 5-year term."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-013838","json":"https://secwatch.observer/filing/0001558370-22-013838.json","markdown":"https://secwatch.observer/filing/0001558370-22-013838.md","text":"https://secwatch.observer/filing/0001558370-22-013838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000155837022013838/0001558370-22-013838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000155837022013838/fencf-20220822x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T22:12:25.963987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}